Dr. Edward Stadtmauer discusses approaches to tailoring induction therapy for newly diagnosed, transplant eligible multiple myeloma patients.
Online PR News – 23-September-2011 – – Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to destruction of bone as well as marrow failure. Presenting a challenge to both academic- and community-based oncologists who treat many kinds of malignancies, multiple myeloma is a relatively small population cancer with only some 20,000 patients diagnosed annually. Consequently, many practitioners may have comparatively little direct experience with the appropriate management of patients with this disease. While not curable at this time, the introduction of novel agents like bortezomib, lenalidomide, and thalidomide have significantly increased life expectancy and quality of life for multiple myeloma patients and this disease is now transitioning, with appropriate care, to one that is more characteristic of a chronic disease. A number of therapeutic options are available and still more are rapidly emerging for the management of newly diagnosed, treatment-naïve multiple myeloma patients. Today, treatment of multiple myeloma needs to be tailored to individual patient needs. Autologous stem cell transplant (ASCT) also remains a vital part of the treatment paradigm for those patients who are eligible.
Edward A. Stadtmauer, MD, director, Bone Marrow and Stem Cell Transplant Program and co-leader of the Hematologic Malignancies Program at the University of Pennsylvania Abramson Cancer Center, recently presented a virtual grand rounds discussion of a real-world, newly diagnosed, transplant eligible, multiple myeloma patient case. In the presentation, Dr. Stadtmauer walks clinicians in a step-by-step process through the patient’s diagnostic workup results, treatment options and key points that should be included in patient education. Dr. Stadtmauer also discusses considerations for tailoring therapy for the patient, including assessment of patient treatment goals, risk-stratification, treatment of comorbidities, prophylaxis and the modification of treatment based on the emergence of side effects, and response to treatment.
More information on this program as well as many other educational opportunities can be found on Managing Myeloma.